Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)· 2022 · 225 citations
2. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial· 2013 · 574 citations
3. Hy's law: predicting serious hepatotoxicity· 2006 · 348 citations
4. Anti-PCSK9 Monotherapy for Hypercholesterolemia· 2014 · 407 citations
5. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe· 2018 · 107 citations